Tyck till om SwePub Sök här!
WFRF:(Brandes A)
Sökning: WFRF:(Brandes A) > Anticoagulation wit...
- 1 av 29
- Föregående post
- Nästa post
- Till träfflistan
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
-
- Kirchhof, P. (författare)
- Atrial Fibrillat Network, Munster, Germany.;Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, Hamburg, Germany.;German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Hamburg, Germany.
-
- Toennis, T. (författare)
- Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, Hamburg, Germany.;German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Hamburg, Germany.
-
- Goette, A. (författare)
- Atrial Fibrillat Network, Munster, Germany.;St Vincenz Hosp Paderborn, Dept Cardiol & Intens Care Med, Paderborn, Germany.
- visa fler...
- Dan, G. -A (författare)
- Ozga, A. -K (författare)
- visa färre...
- Atrial Fibrillat Network, Munster, Germany;Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, Hamburg, Germany.;German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Hamburg, Germany. Univ Heart & Vasc Ctr Hamburg, Dept Cardiol, Hamburg, Germany.;German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Hamburg, Germany. (creator_code:org_t)
- Massachusetts Medical Society, 2023
- 2023
- Engelska.
- Ingår i: New England Journal of Medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 389:13, s. 1167-1179
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- BACKGROUND Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of AHREs in patients without atrial fibrillation (as documented on a conventional electrocardiogram [ECG]) justifies the initiation of anticoagulants is not known. METHODS We conducted an event-driven, double-blind, double-dummy, randomized trial involving patients 65 years of age or older who had AHREs lasting for at least 6 minutes and who had at least one additional risk factor for stroke. Patients were randomly assigned in a 1:1 ratio to receive edoxaban or placebo. The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis. The safety outcome was a composite of death from any cause or major bleeding. RESULTS The analysis population consisted of 2536 patients (1270 in the edoxaban group and 1266 in the placebo group). The mean age was 78 years, 37.4% were women, and the median duration of AHREs was 2.8 hours. The trial was terminated early, at a median follow-up of 21 months, on the basis of safety concerns and the results of an independent, informal assessment of futility for the efficacy of edoxaban; at termination, the planned enrollment had been completed. A primary efficacy outcome event occurred in 83 patients (3.2% per patient-year) in the edoxaban group and in 101 patients (4.0% per patient-year) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.60 to 1.08; P = 0.15). The incidence of stroke was approximately 1% per patient-year in both groups. A safety outcome event occurred in 149 patients (5.9% per patient-year) in the edoxaban group and in 114 patients (4.5% per patient-year) in the placebo group (hazard ratio, 1.31; 95% CI, 1.02 to 1.67; P = 0.03). ECG-diagnosed atrial fibrillation developed in 462 of 2536 patients (18.2% total, 8.7% per patient-year). CONCLUSIONS Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.)
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
- New England Journal of Medicine (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 29
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Kirchhof, P.
- Toennis, T.
- Goette, A.
- Camm, A. J.
- Diener, H. C.
- Becher, N.
- visa fler...
- Bertaglia, E.
- Blomqvist Lundqv ...
- Borlich, M.
- Brandes, A.
- Cabanelas, N.
- Calvert, M.
- Chlouverakis, G.
- Dan, G. -A
- de Groot, J. R.
- Dichtl, W.
- Kravchuk, B.
- Lubinski, A.
- Marijon, E.
- Merkely, B.
- Mont, L.
- Ozga, A. -K
- Rajappan, K.
- Sarkozy, A.
- Scherr, D.
- Sznajder, R.
- Velchev, V.
- Wichterle, D.
- Sehner, S.
- Simantirakis, E.
- Lip, G. Y. H.
- Vardas, P.
- Schotten, U.
- Zapf, A.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- New England Jour ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
